90 completed, 36 terminated, 12 active not recruiting, 7 withdrawn. 54 Phase 2, 50 Not applicable, 33 Phase 1, 10 Phase 3, 4 Early Phase 1.
Follow Stage IIIA Breast Cancer: new trials by email Literature Review of Stage IIIA Breast Cancer trials Research Report on Stage IIIA Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03 TX05 (trastuzumab), Herceptin (trastuzumab) - HER2-positive Breast Cancer, Early-stage Breast Cancer | Phase 3 | Completed | Tanvex BioPharma USA, Inc. | 338 | 2019-08-20 | 2022-10-26 |
| Exercise Intervention in Targeting Adiposity and Inflammation With Movement to Improve Prognosis in Breast Cancer Exercise Intervention, Informational Intervention, Laboratory Biomarker Analysis - Cancer Survivor, Central Obesity | Not applicable | Withdrawn | University of Southern California | 2019-07-29 | 2019-10-24 | |
| Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer Anti-OX40 Antibody PF-04518600, Avelumab, Binimetinib - Stage III Breast Cancer, Stage IIIA Breast Cancer | Phase 2 | Active not recruiting | Laura Huppert, MD, BA | 145 | 2019-07-08 | 2026-04-17 |
| Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer Atezolizumab, Cobimetinib, Idasanutlin - Stage III Breast Cancer, Stage IIIA Breast Cancer | Phase 1 / Phase 2 | Terminated | Vanderbilt-Ingram Cancer Center | 12 | 2018-07-10 | 2021-08-11 |
| Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer TX05 (trastuzumab), Herceptin®, Paclitaxel - Breast Cancer, Breast Neoplasms | Phase 3 | Completed | Tanvex BioPharma USA, Inc. | 809 | 2018-06-28 | 2022-01-14 |
| Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer Radiation Therapy, Questionnaire Administration, Quality-of-Life Assessment - Ductal Breast Carcinoma, Invasive Breast Carcinoma | Phase 3 | Active not recruiting | Alliance for Clinical Trials in Oncology | 898 | 2018-03-12 | 2026-02-24 |
| Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners Cognitive Behavior Therapy, Quality-of-Life Assessment, Questionnaire Administration - Malignant Female Reproductive System Neoplasm, Malignant Hepatobiliary Neoplasm | Not applicable | Completed | Rutgers, The State University of New Jersey | 14 | 2017-12-06 | 2021-04-08 |
| 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer Utomilumab, Trastuzumab, Ado-Trastuzumab Emtansine - HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma | Phase 1 | Completed | George W. Sledge Jr. | 18 | 2017-10-30 | 2022-10-19 |
| Aerobic and Strength Training Exercise in Improving Fitness and Arm Health During and After Radiation Therapy in Patients With Stage II-III Breast Cancer Best Practice, Exercise Intervention, Quality-of-Life Assessment - Stage II Breast Cancer, Stage IIA Breast Cancer | Not applicable | Completed | Ohio State University Comprehensive Cancer Center | 4 | 2017-08-30 | 2023-12-14 |
| Exercise in Targeting Metabolic Dysregulation in Stage I-III Breast or Prostate Cancer Survivors Exercise Intervention, Laboratory Biomarker Analysis, Polar heart rate monitor - Cancer Survivor, No Evidence of Disease | Not applicable | Terminated | University of Southern California | 23 | 2017-08-17 | 2025-09-29 |
| Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer Biopsy of Breast, Copanlisib, Laboratory Biomarker Analysis - Estrogen Receptor Positive, HER2/Neu Negative | Phase 1 | Terminated | Jonsson Comprehensive Cancer Center | 10 | 2017-08-02 | 2022-09-26 |
| Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer Alisertib, Fulvestrant, Laboratory Biomarker Analysis - Estrogen Receptor Status, HER2/Neu Negative | Phase 2 | Completed | Mayo Clinic | 96 | 2017-07-06 | 2026-09-24 |
| Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery Capecitabine, Laboratory Biomarker Analysis, Pembrolizumab - Estrogen Receptor Negative, HER2/Neu Negative | Phase 2 | Unknown | Northwestern University | 30 | 2017-05-25 | 2020-07-13 |
| Ultrasound in Detecting Taxane-Induced Neuropathy in Patients With Breast Cancer Biopsy, Questionnaire Administration, Ultrasound Tomography - Peripheral Neuropathy, Stage 0 Breast Cancer | Not applicable | Completed | Wake Forest University Health Sciences | 20 | 2017-05-11 | 2024-04-08 |
| Assessing the Accuracy of Tumor Biopsies After Chemotherapy to Determine if Patients Can Avoid Breast Surgery Biopsy of Breast - Invasive Breast Carcinoma, Stage II Breast Cancer | Phase 2 | Completed | NRG Oncology | 105 | 2017-04-13 | 2025-05-22 |
| Mindfulness Meditation or Survivorship Education in Improving Behavioral Symptoms in Younger Stage 0-III Breast Cancer Survivors (Pathways to Wellness) Educational Intervention, Laboratory Biomarker Analysis, Meditation Therapy - Cancer Survivor, Early-Stage Breast Carcinoma | Not applicable | Unknown | Jonsson Comprehensive Cancer Center | 96 | 2017-02-20 | 2022-07-21 |
| Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery Fulvestrant, Laboratory Biomarker Analysis, Palbociclib - Estrogen Receptor and/or Progesterone Receptor Positive, HER2/Neu Negative | Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 14 | 2017-02-16 | 2025-12-19 |
| Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca Doxorubicin, Cyclophosphamide, Paclitaxel - Breast Adenocarcinoma, Estrogen Receptor- Negative Breast Cancer | Phase 2 | Active not recruiting | Virginia Commonwealth University | 46 | 2017-01-24 | 2026-07-01 |
| Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors Carboplatin, Cisplatin, Palbociclib - Solid Neoplasm, Stage III Pancreatic Cancer | Phase 1 | Completed | Emory University | 71 | 2016-10-24 | 2023-10-10 |
| S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER) Preventive Intervention, Quality-of-Life Assessment, Questionnaire Administration - Febrile Neutropenia, Stage 0 Breast Cancer | Not applicable | Completed | SWOG Cancer Research Network | 3665 | 2016-10-07 | 2022-10-20 |
Showing 20 of 148. Sign in to see all of them.
Breast Neoplasms (148) · Breast Neoplasms, Male (27) · Triple Negative Breast Neoplasms (18) · Breast Carcinoma In Situ (16) · Carcinoma, Intraductal, Noninfiltrating (12) · Carcinoma, Ovarian Epithelial (9) · Inflammatory Breast Neoplasms (9) · Carcinoma, Renal Cell (7) · Depression (7) · Testicular Neoplasms (7) · Burkitt Lymphoma (6) · Carcinoma, Non-Small-Cell Lung (6) · Hodgkin Disease (6) · Leukemia, Lymphocytic, Chronic, B-Cell (6) · Lymphoma, Follicular (6)
Breast Diseases (148) · Neoplasms by Site (148) · Skin Diseases (148) · Skin and Connective Tissue Diseases (148) · Neoplasms (146) · Neoplasms by Histologic Type (42) · Carcinoma (39) · Neoplasms, Glandular and Epithelial (39) · Adenocarcinoma (23) · Carcinoma in Situ (21) · Urogenital Diseases (20) · Urogenital Neoplasms (20) · Female Urogenital Diseases (18) · Female Urogenital Diseases and Pregnancy Complications (18) · Neoplasms, Ductal, Lobular, and Medullary (18)
Taxes (22) · Paclitaxel (21) · Cyclophosphamide (20) · Doxorubicin (17) · Trastuzumab (16) · Carboplatin (11) · Early Intervention, Educational (10) · Methods (9) · Anastrozole (8) · Capecitabine (8) · Letrozole (8) · Magnetic Resonance Spectroscopy (8) · Radiotherapy (8) · Radiation (7) · Tamoxifen (7)
National Cancer Institute (NCI) (23) · University of Washington (14) · University of Southern California (13) · City of Hope Medical Center (9) · Wake Forest University Health Sciences (9) · Ohio State University Comprehensive Cancer Center (8) · Rutgers, The State University of New Jersey (5) · Mayo Clinic (4) · Northwestern University (4) · Alliance for Clinical Trials in Oncology (3) · Case Comprehensive Cancer Center (3) · Emory University (3) · Fred Hutchinson Cancer Center (3) · Roswell Park Cancer Institute (3) · Stanford University (3)
United States (141) · Canada (8) · Puerto Rico (4) · Belarus (2) · Chile (2) · Georgia (2) · Hungary (2) · India (2) · Mexico (2) · Peru (2) · Philippines (2) · Russia (2) · Ukraine (2) · Japan (1) · South Africa (1)
Hannah Linden (4) · Agustin Garcia (2) · Anna Wu (2) · Bonnie Mills, PhD (2) · Christina Dieli-Conwright, Ph.D. (2) · Dawn Hershman (2) · Jennifer Specht (2) · Joanne Mortimer (2) · Joseph Sparano (2) · Lupe Salazar (2) · Sharon Manne (2) · Vered Stearns (2) · William Hundley (2) · Agustin Garcia, MD (1) · Aman Buzdar (1)
PMID 18650156, PMID 18974373, PMID 22827973, PMID 24068539, PMID 24095609, PMID 24154719, PMID 24210070, PMID 24239210, PMID 24708832, PMID 24881463, PMID 25495490, PMID 25965900, PMID 26006067, PMID 26059540, PMID 26062933, PMID 26092816, PMID 26276750, PMID 26359256, PMID 26611425, PMID 27022111, PMID 27044936, PMID 27520860, PMID 28045625, PMID 28453704, PMID 28560655, PMID 28764748, PMID 28817727, PMID 28911092, PMID 29233615, PMID 29356607, PMID 29440043, PMID 29863451, PMID 29961039, PMID 30193295, PMID 30340503, PMID 30535101, PMID 30549145, PMID 30850872, PMID 30920602, PMID 31236810, PMID 31269914, PMID 31309977, PMID 31618131, PMID 31833973, PMID 32060053, PMID 32808383, PMID 33292676, PMID 33740205, PMID 33929533, PMID 34018031
P30CA012197 (6), P30CA014089 (5), P30CA015704 (5), P30CA072720 (5), P30CA013330 (4), N01CM62204 (3), P30CA014520 (3), P30CA015083 (3), P30CA016672 (3), U10CA031946 (3), N01CN35159 (2), P30CA016056 (2), P30CA016059 (2), P30CA036727 (2), P30CA060553 (2)